Pfizer Saudi Limited signed an exclusive commercial agreement with Tabuk Pharmaceuticals. The deal will permit Pfizer to advertise and promote branded and high-value generic drugs, such as medicines that provide treatment for kidney dialysis, kidney transplant, urology, and the central nervous system. This agreement is part of a larger Vision 2030 effort to strengthen local manufacturing capabilities. Pfizer started production at a $50 million plant in Saudi Arabia in January.
Pfizer Signs Commercial Agreement
You also might be interested in
The King Abdullah Petroleum Studies and Research Centre’s (KAPSARC) headquarters[...]
February 25-28, 2018 Minneapolis Convention Center| Minneapolis, MN SME Annual[...]
Pfizer Saudi Limited opened its $50 million manufacturing facility at[...]